Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Gemini agents verify Signal's code as Anthropic opens its roadshow [Nov 11 2026] cover art

Gemini agents verify Signal's code as Anthropic opens its roadshow [Nov 11 2026]

Gemini agents verify Signal's code as Anthropic opens its roadshow [Nov 11 2026]

Listen for free

View show details
About this listen
Google DeepMind said agents powered by Gemini Carbon generated "over six million lines of Lean" to produce machine-checked proofs that the compiled code of libsignal, the Signal protocol's reference implementation, meets its core security properties. DeepMind says "our verification process took just four weeks" and that agents flagged "just one percent of the codebase" for a second look by a human. CyberInsider reports the work covered an executable built for 64-bit Arm processors from version 0.105.4 of libsignal, with side channels and the rest of the messaging app outside the analysis. Microsoft Research published a backdoor method it calls Lazarus: "weight-reprogramming fewer than 10 dormant neurons in an LLM, is enough to backdoor an agent built on it, and requires no training." The post says the model passes standard evals and behaves normally until a trigger appears, and gives a date change into 2027 as an example trigger that makes the agent download and run an attacker's code. Microsoft Threat Intelligence says it has not observed threat actors using the technique. Anthropic launched its IPO roadshow at $70.00 to $78.00 per share for 825,000,000 Class A shares. CNBC reports a fully diluted valuation of up to $1.405 trillion, against the $965 billion valuation announced in May, and a $26 billion private placement of Class N stock to AMD, Broadcom, Google, Micron, Microsoft, Nvidia and TSMC; TSMC's board separately approved up to US$500 million for Anthropic shares at the IPO price and up to US$500 million for OpenAI preferred stock. Railway put unauthorized spend on AI provider keys stolen in its October breach at "~$740,000", and Nature Medicine reported a deep-learning TROP2 biomarker associated with median progression-free survival of 7.2 versus 4.0 months on datopotamab deruxtecan.
adbl_web_anon_alc_button_suppression_t1
No reviews yet